Author:
Xu Hong-Rong,Zhang Jin-Wen,Chen Wei-li,Ning Zhi-Qiang,Li Xue-Ning
Funder
the Shenzhen Science and Technology Innovation Committee
National Foundation for Science and Technology Development
National Science and Technology Significant Project in the category “New Drug Initiative”
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference26 articles.
1. Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, et al. IDF diabetes atlas, sixth edition. International Diabetes Federation. 2013.
2. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 1900;365(9467):1333–46.
3. Brunzell JD, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg. Diabetes Care. 2005;28(12):2985–6.
4. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem. 1998;273(49):32679.
5. Elasy TA, Griffin M. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association: response to Nesto. Pediatr Emerg Care. 2008;108(23):344–5.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献